{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:52:19Z","timestamp":1772783539694,"version":"3.50.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00018-013-1502-2","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T13:42:27Z","timestamp":1384263747000},"page":"1417-1438","source":"Crossref","is-referenced-by-count":25,"title":["Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology"],"prefix":"10.1007","volume":"71","author":[{"given":"L\u00edgia Catarina","family":"Gomes-da-Silva","sequence":"first","affiliation":[]},{"given":"S\u00e9rgio","family":"Sim\u00f5es","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"issue":"1","key":"1502_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10\u201329. doi: 10.3322\/caac.20138","journal-title":"CA Cancer J Clin"},{"key":"1502_CR2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57\u201370","journal-title":"Cell"},{"issue":"5","key":"1502_CR3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136(5):823\u2013837. doi: 10.1016\/j.cell.2009.02.024","journal-title":"Cell"},{"issue":"2","key":"1502_CR4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/path.2806","volume":"223","author":"TA Farazi","year":"2011","unstructured":"Farazi TA, Spitzer JI, Morozov P, Tuschl T (2011) miRNAs in human cancer. J Pathol 223(2):102\u2013115. doi: 10.1002\/path.2806","journal-title":"J Pathol"},{"issue":"2","key":"1502_CR5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nbt1052","volume":"23","author":"D Siolas","year":"2005","unstructured":"Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, Hannon GJ, Cleary MA (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23(2):227\u2013231. doi: 10.1038\/nbt1052","journal-title":"Nat Biotechnol"},{"issue":"6836","key":"1502_CR6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494\u2013498. doi: 10.1038\/35078107","journal-title":"Nature"},{"issue":"2\u20133","key":"1502_CR7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","volume":"59","author":"L Aagaard","year":"2007","unstructured":"Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59(2\u20133):75\u201386","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"1502_CR8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","volume":"6","author":"A Fougerolles de","year":"2007","unstructured":"de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6(6):443\u2013453","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1502_CR9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2353\/ajpath.2007.070120","volume":"171","author":"R Bhindi","year":"2007","unstructured":"Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun LQ, Khachigian LM (2007) Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol 171(4):1079\u20131088","journal-title":"Am J Pathol"},{"issue":"1","key":"1502_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1758-907X-1-14","volume":"1","author":"AK Vaishnaw","year":"2010","unstructured":"Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, de Fougerolles T, Maraganore J (2010) A status report on RNAi therapeutics. Silence 1(1):14. doi: 10.1186\/1758-907X-1-14","journal-title":"Silence"},{"issue":"6","key":"1502_CR11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nbt831","volume":"21","author":"AL Jackson","year":"2003","unstructured":"Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21(6):635\u2013637. doi: 10.1038\/nbt831","journal-title":"Nat Biotechnol"},{"key":"1502_CR12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2199-9-60","volume":"9","author":"C Tschuch","year":"2008","unstructured":"Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A, Barrionuevo LS, Lichter P, Mertens D (2008) Off-target effects of siRNA specific for GFP. BMC Mol Biol 9:60. doi: 10.1186\/1471-2199-9-60","journal-title":"BMC Mol Biol"},{"issue":"7","key":"1502_CR13","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1261\/rna.28106","volume":"12","author":"Y Fedorov","year":"2006","unstructured":"Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, Leake D, Marshall WS, Khvorova A (2006) Off-target effects by siRNA can induce toxic phenotype. RNA 12(7):1188\u20131196. doi: 10.1261\/rna.28106","journal-title":"RNA"},{"issue":"1","key":"1502_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/bc9004365","volume":"21","author":"LS Mendonca","year":"2010","unstructured":"Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simoes S (2010) Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 21(1):157\u2013168. doi: 10.1021\/bc9004365","journal-title":"Bioconjug Chem"},{"issue":"3","key":"1502_CR15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","volume":"11","author":"V Hornung","year":"2005","unstructured":"Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11(3):263\u2013270. doi: 10.1038\/nm1191","journal-title":"Nat Med"},{"key":"1502_CR16","first-page":"41","volume":"487","author":"M Sioud","year":"2009","unstructured":"Sioud M (2009) Deciphering the code of innate immunity recognition of siRNAs. Methods Mol Biol 487:41\u201359","journal-title":"Methods Mol Biol"},{"issue":"4","key":"1502_CR17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","volume":"23","author":"AD Judge","year":"2005","unstructured":"Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23(4):457\u2013462. doi: 10.1038\/nbt1081","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1502_CR18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jmb.2005.03.013","volume":"348","author":"M Sioud","year":"2005","unstructured":"Sioud M (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348(5):1079\u20131090. doi: 10.1016\/j.jmb.2005.03.013","journal-title":"J Mol Biol"},{"issue":"5","key":"1502_CR19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/eji.200535708","volume":"36","author":"M Sioud","year":"2006","unstructured":"Sioud M (2006) Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2\u2032-hydroxyl uridines in immune responses. Eur J Immunol 36(5):1222\u20131230. doi: 10.1002\/eji.200535708","journal-title":"Eur J Immunol"},{"issue":"9","key":"1502_CR20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ncb1038","volume":"5","author":"CA Sledz","year":"2003","unstructured":"Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5(9):834\u2013839. doi: 10.1038\/ncb1038","journal-title":"Nat Cell Biol"},{"issue":"3","key":"1502_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ng1173","volume":"34","author":"AJ Bridge","year":"2003","unstructured":"Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R (2003) Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34(3):263\u2013264. doi: 10.1038\/ng1173","journal-title":"Nat Genet"},{"issue":"5663","key":"1502_CR22","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303(5663):1526\u20131529. doi: 10.1126\/science.1093620","journal-title":"Science"},{"issue":"7187","key":"1502_CR23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","volume":"452","author":"ME Kleinman","year":"2008","unstructured":"Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Kariko K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452(7187):591\u2013597. doi: 10.1038\/nature06765","journal-title":"Nature"},{"issue":"17","key":"1502_CR24","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1073\/pnas.0812317106","volume":"106","author":"WG Cho","year":"2009","unstructured":"Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, Green MG, Baffi JZ, Ambati BK, De Falco M, Alexander JS, Brunetti A, De Falco S, Ambati J (2009) Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci USA 106(17):7137\u20137142. doi: 10.1073\/pnas.0812317106","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1502_CR25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1593\/neo.92106","volume":"12","author":"A Paone","year":"2010","unstructured":"Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, De Cesaris P, Ziparo E, Del Bufalo D, Sitkovsky MV, Filippini A, Riccioli A (2010) Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia 12(7):539\u2013549","journal-title":"Neoplasia"},{"issue":"2","key":"1502_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2007.179","volume":"19","author":"A Judge","year":"2008","unstructured":"Judge A, MacLachlan I (2008) Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19(2):111\u2013124. doi: 10.1089\/hum.2007.179","journal-title":"Hum Gene Ther"},{"issue":"5","key":"1502_CR27","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1166\/jnn.2008.319","volume":"8","author":"JN Moreira","year":"2008","unstructured":"Moreira JN, Santos A, Moura V, Pedroso de Lima MC, Simoes S (2008) Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J Nanosci Nanotechnol 8(5):2187\u20132204","journal-title":"J Nanosci Nanotechnol"},{"issue":"19\u201320","key":"1502_CR28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.drudis.2008.05.007","volume":"13","author":"JK Watts","year":"2008","unstructured":"Watts JK, Deleavey GF, Damha MJ (2008) Chemically modified siRNA: tools and applications. Drug Discov Today 13(19\u201320):842\u2013855. doi: 10.1016\/j.drudis.2008.05.007","journal-title":"Drug Discov Today"},{"issue":"7","key":"1502_CR29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1261\/rna.30706","volume":"12","author":"AL Jackson","year":"2006","unstructured":"Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W, Khvorova A, Linsley PS (2006) Position-specific chemical modification of siRNAs reduces \u201coff-target\u201d transcript silencing. RNA 12(7):1197\u20131205. doi: 10.1261\/rna.30706","journal-title":"RNA"},{"issue":"9","key":"1502_CR30","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","volume":"9","author":"YL Chiu","year":"2003","unstructured":"Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9(9):1034\u20131048","journal-title":"RNA"},{"issue":"8","key":"1502_CR31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","volume":"23","author":"DV Morrissey","year":"2005","unstructured":"Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23(8):1002\u20131007. doi: 10.1038\/nbt1122","journal-title":"Nat Biotechnol"},{"issue":"6","key":"1502_CR32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hep.20702","volume":"41","author":"DV Morrissey","year":"2005","unstructured":"Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA, Zinnen S (2005) Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41(6):1349\u20131356. doi: 10.1002\/hep.20702","journal-title":"Hepatology"},{"issue":"7089","key":"1502_CR33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","volume":"441","author":"TS Zimmermann","year":"2006","unstructured":"Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I (2006) RNAi-mediated gene silencing in non-human primates. Nature 441(7089):111\u2013114. doi: 10.1038\/nature04688","journal-title":"Nature"},{"issue":"3","key":"1502_CR34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","volume":"13","author":"AD Judge","year":"2006","unstructured":"Judge AD, Bola G, Lee AC, MacLachlan I (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13(3):494\u2013505. doi: 10.1016\/j.ymthe.2005.11.002","journal-title":"Mol Ther"},{"issue":"12","key":"1502_CR35","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/eji.200636617","volume":"36","author":"SS Diebold","year":"2006","unstructured":"Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C (2006) Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 36(12):3256\u20133267. doi: 10.1002\/eji.200636617","journal-title":"Eur J Immunol"},{"issue":"1","key":"1502_CR36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbrc.2007.06.177","volume":"361","author":"M Sioud","year":"2007","unstructured":"Sioud M, Furset G, Cekaite L (2007) Suppression of immunostimulatory siRNA-driven innate immune activation by 2\u2032-modified RNAs. Biochem Biophys Res Commun 361(1):122\u2013126. doi: 10.1016\/j.bbrc.2007.06.177","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"1502_CR37","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.mt.6300240","volume":"15","author":"M Robbins","year":"2007","unstructured":"Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I (2007) 2\u2032-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 15(9):1663\u20131669. doi: 10.1038\/sj.mt.6300240","journal-title":"Mol Ther"},{"issue":"7","key":"1502_CR38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.imbio.2009.09.003","volume":"215","author":"S Hamm","year":"2010","unstructured":"Hamm S, Latz E, Hangel D, Muller T, Yu P, Golenbock D, Sparwasser T, Wagner H, Bauer S (2010) Alternating 2\u2032-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology 215(7):559\u2013569. doi: 10.1016\/j.imbio.2009.09.003","journal-title":"Immunobiology"},{"issue":"10","key":"1502_CR39","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1089\/hum.2008.131","volume":"19","author":"M Robbins","year":"2008","unstructured":"Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, McClintock K, MacLachlan I (2008) Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19(10):991\u2013999. doi: 10.1089\/hum.2008.131","journal-title":"Hum Gene Ther"},{"issue":"23","key":"1502_CR40","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1073\/pnas.0402486101","volume":"101","author":"Q Ge","year":"2004","unstructured":"Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 101(23):8676\u20138681. doi: 10.1073\/pnas.0402486101","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"1502_CR41","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1073\/pnas.0402630101","volume":"101","author":"SM Tompkins","year":"2004","unstructured":"Tompkins SM, Lo CY, Tumpey TM, Epstein SL (2004) Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 101(23):8682\u20138686. doi: 10.1073\/pnas.0402630101","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1502_CR42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.bbrc.2006.11.059","volume":"352","author":"G Furset","year":"2007","unstructured":"Furset G, Sioud M (2007) Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 352(3):642\u2013649. doi: 10.1016\/j.bbrc.2006.11.059","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1502_CR43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1593\/tlo.09154","volume":"2","author":"PO Iversen","year":"2009","unstructured":"Iversen PO, Semaeva E, Sorensen DR, Wiig H, Sioud M (2009) Dendritic cells loaded with tumor antigens and a dual immunostimulatory and anti-interleukin 10-specific small interference RNA prime t lymphocytes against leukemic cells. Transl Oncol 2(4):242\u2013246","journal-title":"Transl Oncol"},{"key":"1502_CR44","author":"N Khairuddin","year":"2011","unstructured":"Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA (2011) siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol. doi: 10.1038\/icb.2011.19","journal-title":"Immunol Cell Biol"},{"key":"1502_CR45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-59745-210-6_3","volume":"437","author":"PY Lu","year":"2008","unstructured":"Lu PY, Woodle MC (2008) Delivering small interfering RNA for novel therapeutics. Methods Mol Biol 437:93\u2013107. doi: 10.1007\/978-1-59745-210-6_3","journal-title":"Methods Mol Biol"},{"issue":"7228","key":"1502_CR46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","volume":"457","author":"D Castanotto","year":"2009","unstructured":"Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457(7228):426\u2013433. doi: 10.1038\/nature07758","journal-title":"Nature"},{"issue":"12","key":"1502_CR47","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","volume":"2","author":"D Bumcrot","year":"2006","unstructured":"Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2(12):711\u2013719. doi: 10.1038\/nchembio839","journal-title":"Nat Chem Biol"},{"issue":"7","key":"1502_CR48","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/ar300048p","volume":"45","author":"LC Gomes-da-Silva","year":"2012","unstructured":"Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simoes S, Moreira JN (2012) Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 45(7):1163\u20131171. doi: 10.1021\/ar300048p","journal-title":"Acc Chem Res"},{"issue":"4","key":"1502_CR49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/hum.2008.026","volume":"19","author":"JJ Rossi","year":"2008","unstructured":"Rossi JJ (2008) Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 19(4):313\u2013317","journal-title":"Hum Gene Ther"},{"issue":"3","key":"1502_CR50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2006","volume":"8","author":"DH Kim","year":"2007","unstructured":"Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8(3):173\u2013184. doi: 10.1038\/nrg2006","journal-title":"Nat Rev Genet"},{"issue":"36","key":"1502_CR51","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","volume":"49","author":"K Knop","year":"2010","unstructured":"Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 49(36):6288\u20136308. doi: 10.1002\/anie.200902672","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"1502_CR52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","volume":"107","author":"J Heyes","year":"2005","unstructured":"Heyes J, Palmer L, Bremner K, MacLachlan I (2005) Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 107(2):276\u2013287. doi: 10.1016\/j.jconrel.2005.06.014","journal-title":"J Control Release"},{"issue":"2","key":"1502_CR53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28(2):172\u2013176. doi: 10.1038\/nbt.1602","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1502_CR54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11095-004-1873-z","volume":"22","author":"LB Jeffs","year":"2005","unstructured":"Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I (2005) A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22(3):362\u2013372","journal-title":"Pharm Res"},{"issue":"12","key":"1502_CR55","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/504267","volume":"193","author":"TW Geisbert","year":"2006","unstructured":"Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I (2006) Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 193(12):1650\u20131657. doi: 10.1086\/504267","journal-title":"J Infect Dis"},{"issue":"1\u20132","key":"1502_CR56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","volume":"1510","author":"SC Semple","year":"2001","unstructured":"Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ, Scherrer P (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510(1\u20132):152\u2013166 (pii:S0005-2736(00)00343-6)","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1502_CR57","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0006-3495(01)76202-9","volume":"80","author":"N Maurer","year":"2001","unstructured":"Maurer N, Wong KF, Stark H, Louie L, McIntosh D, Wong T, Scherrer P, Semple SC, Cullis PR (2001) Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 80(5):2310\u20132326. doi: 10.1016\/S0006-3495(01)76202-9","journal-title":"Biophys J"},{"issue":"2","key":"1502_CR58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbamem.2005.02.001","volume":"1669","author":"E Ambegia","year":"2005","unstructured":"Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I (2005) Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 1669(2):155\u2013163. doi: 10.1016\/j.bbamem.2005.02.001","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1502_CR59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1172\/JCI37515","volume":"119","author":"AD Judge","year":"2009","unstructured":"Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I (2009) Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119(3):661\u2013673. doi: 10.1172\/JCI37515","journal-title":"J Clin Invest"},{"issue":"2","key":"1502_CR60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.gt.3300821","volume":"6","author":"JJ Wheeler","year":"1999","unstructured":"Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, Hope MJ, Scherrer P, Cullis PR (1999) Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 6(2):271\u2013281. doi: 10.1038\/sj.gt.3300821","journal-title":"Gene Ther"},{"issue":"6","key":"1502_CR61","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jhep.2011.05.039","volume":"55","author":"LH Reddy","year":"2011","unstructured":"Reddy LH, Couvreur P (2011) Nanotechnology for therapy and imaging of liver diseases. J Hepatol 55(6):1461\u20131466. doi: 10.1016\/j.jhep.2011.05.039","journal-title":"J Hepatol"},{"issue":"7","key":"1502_CR62","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, Jayaraman M, Rajeev KG, Cantley WL, Dorkin JR, Butler JS, Qin L, Racie T, Sprague A, Fava E, Zeigerer A, Hope MJ, Zerial M, Sah DW, Fitzgerald K, Tracy MA, Manoharan M, Koteliansky V, Fougerolles A, Maier MA (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18(7):1357\u20131364. doi: 10.1038\/mt.2010.85","journal-title":"Mol Ther"},{"issue":"9729","key":"1502_CR63","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","volume":"375","author":"TW Geisbert","year":"2010","unstructured":"Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729):1896\u20131905. doi: 10.1016\/S0140-6736(10)60357-1","journal-title":"Lancet"},{"issue":"4","key":"1502_CR64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1261\/rna.2546011","volume":"17","author":"X Lin","year":"2011","unstructured":"Lin X, Li L, Wang R, Wilcox D, Zhao X, Song J, Huang X, Hansen TM, Dande P, Wada C, Hubbard RD, Kohlbrenner WM, Fesik SW, Shen Y (2011) A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA 17(4):603\u2013612. doi: 10.1261\/rna.2546011","journal-title":"RNA"},{"key":"1502_CR65","author":"L Li","year":"2011","unstructured":"Li L, Wang R, Wilcox D, Zhao X, Song J, Lin X, Kohlbrenner WM, Fesik SW, Shen Y (2011) Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther. doi: 10.1038\/gt.2011.146","journal-title":"Gene Ther"},{"issue":"1","key":"1502_CR66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","volume":"271","author":"RK Jain","year":"1994","unstructured":"Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271(1):58\u201365","journal-title":"Sci Am"},{"issue":"11","key":"1502_CR67","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"RK Jain","year":"2010","unstructured":"Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7(11):653\u2013664. doi: 10.1038\/nrclinonc.2010.139","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1502_CR68","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1023\/A:1025785505977","volume":"20","author":"SH Jang","year":"2003","unstructured":"Jang SH, Wientjes MG, Lu D, Au JL (2003) Drug delivery and transport to solid tumors. Pharm Res 20(9):1337\u20131350","journal-title":"Pharm Res"},{"issue":"5","key":"1502_CR69","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/sj.bjc.6605551","volume":"102","author":"JM Heddleston","year":"2010","unstructured":"Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN (2010) Hypoxia inducible factors in cancer stem cells. Br J Cancer 102(5):789\u2013795. doi: 10.1038\/sj.bjc.6605551","journal-title":"Br J Cancer"},{"issue":"6","key":"1502_CR70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417\u2013427. doi: 10.1038\/nrd3455","journal-title":"Nat Rev Drug Discov"},{"key":"1502_CR71","doi-asserted-by":"crossref","unstructured":"Gomes CP, Gomes-da-Silva LC, Ramalho JS, de Lima MC, Simoes S, Moreira JN (2013) Impact Of Plk-1 Silencing On Endothelial Cells And Cancer Cells Of Diverse Histological Origin. Curr Gene Ther 13(3):189\u2013201 (pii:CGT-EPUB-20130325-3)","DOI":"10.2174\/1566523211313030004"},{"issue":"3","key":"1502_CR72","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136\u2013151. doi: 10.1016\/j.addr.2010.04.009","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1502_CR73","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, Frank-Kamenetsky M, Yip KN, Alvarez R, Sah DW, de Fougerolles A, Fitzgerald K, Koteliansky V, Akinc A, Langer R, Anderson DG (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107(5):1864\u20131869. doi: 10.1073\/pnas.0910603106","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1502_CR74","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/mt.2010.39","volume":"18","author":"Y Liu","year":"2010","unstructured":"Liu Y, Huang L (2010) Designer lipids advance systemic siRNA delivery. Mol Ther 18(4):669\u2013670. doi: 10.1038\/mt.2010.39","journal-title":"Mol Ther"},{"issue":"6","key":"1502_CR75","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/bc034125f","volume":"14","author":"NC Bellocq","year":"2003","unstructured":"Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14(6):1122\u20131132. doi: 10.1021\/bc034125f","journal-title":"Bioconjug Chem"},{"issue":"3","key":"1502_CR76","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/mp900015y","volume":"6","author":"ME Davis","year":"2009","unstructured":"Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6(3):659\u2013668. doi: 10.1021\/mp900015y","journal-title":"Mol Pharm"},{"issue":"7","key":"1502_CR77","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-06-2218","volume":"13","author":"JD Heidel","year":"2007","unstructured":"Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME (2007) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13(7):2207\u20132215. doi: 10.1158\/1078-0432.CCR-06-2218","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1502_CR78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/bit.21668","volume":"99","author":"DW Bartlett","year":"2008","unstructured":"Bartlett DW, Davis ME (2008) Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 99(4):975\u2013985. doi: 10.1002\/bit.21668","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"1502_CR79","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jconrel.2012.01.045","volume":"159","author":"MA Rahman","year":"2012","unstructured":"Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM (2012) Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release 159(3):384\u2013392. doi: 10.1016\/j.jconrel.2012.01.045","journal-title":"J Control Release"},{"issue":"16","key":"1502_CR80","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","volume":"13","author":"A Santel","year":"2006","unstructured":"Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Loffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J (2006) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13(16):1222\u20131234. doi: 10.1038\/sj.gt.3302777","journal-title":"Gene Ther"},{"issue":"18","key":"1502_CR81","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/sj.gt.3302778","volume":"13","author":"A Santel","year":"2006","unstructured":"Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B, Loffler K, Fechtner M, Rohl T, Fisch G, Dames S, Arnold W, Giese K, Klippel A, Kaufmann J (2006) RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 13(18):1360\u20131370. doi: 10.1038\/sj.gt.3302778","journal-title":"Gene Ther"},{"issue":"23","key":"1502_CR82","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1158\/0008-5472.CAN-08-2428","volume":"68","author":"M Aleku","year":"2008","unstructured":"Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Roder N, Loffler K, Lange C, Fechtner M, Mopert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufmann J (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68(23):9788\u20139798. doi: 10.1158\/0008-5472.CAN-08-2428","journal-title":"Cancer Res"},{"issue":"22","key":"1502_CR83","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-10-1994","volume":"16","author":"A Santel","year":"2010","unstructured":"Santel A, Aleku M, Roder N, Mopert K, Durieux B, Janke O, Keil O, Endruschat J, Dames S, Lange C, Eisermann M, Loffler K, Fechtner M, Fisch G, Vank C, Schaeper U, Giese K, Kaufmann J (2010) Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16(22):5469\u20135480. doi: 10.1158\/1078-0432.CCR-10-1994","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1502_CR84","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ejcb.2012.03.010","volume":"91","author":"K Mopert","year":"2012","unstructured":"Mopert K, Loffler K, Roder N, Kaufmann J, Santel A (2012) Depletion of protein kinase N3 (PKN3) impairs actin and adherens junctions dynamics and attenuates endothelial cell activation. Eur J Cell Biol 91(9):694\u2013705. doi: 10.1016\/j.ejcb.2012.03.010","journal-title":"Eur J Cell Biol"},{"issue":"2","key":"1502_CR85","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)35177-8","volume":"291","author":"Y Gutierrez-Puente","year":"1999","unstructured":"Gutierrez-Puente Y, Tari AM, Stephens C, Rosenblum M, Guerra RT, Lopez-Berestein G (1999) Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J Pharmacol Exp Ther 291(2):865\u2013869","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"1502_CR86","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","volume":"65","author":"CN Landen Jr","year":"2005","unstructured":"Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65(15):6910\u20136918. doi: 10.1158\/0008-5472.CAN-05-0530","journal-title":"Cancer Res"},{"issue":"12","key":"1502_CR87","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4161\/cbt.5.12.3468","volume":"5","author":"CN Landen","year":"2006","unstructured":"Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK (2006) Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5(12):1708\u20131713 (pii:3468)","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"1502_CR88","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4161\/cbt.8.11.8523","volume":"8","author":"MM Shahzad","year":"2009","unstructured":"Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK (2009) Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8(11):1027\u20131034 (pii:8523)","journal-title":"Cancer Biol Ther"},{"issue":"13","key":"1502_CR89","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.addr.2009.06.003","volume":"61","author":"R Gaspar","year":"2009","unstructured":"Gaspar R, Duncan R (2009) Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 61(13):1220\u20131231. doi: 10.1016\/j.addr.2009.06.003","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1502_CR90","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/med.20090","volume":"27","author":"PP Karmali","year":"2007","unstructured":"Karmali PP, Chaudhuri A (2007) Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev 27(5):696\u2013722. doi: 10.1002\/med.20090","journal-title":"Med Res Rev"},{"issue":"3","key":"1502_CR91","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","volume":"292","author":"ET Dams","year":"2000","unstructured":"Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292(3):1071\u20131079","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1502_CR92","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2005.04.003","volume":"105","author":"T Ishida","year":"2005","unstructured":"Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H (2005) Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 105(3):305\u2013317. doi: 10.1016\/j.jconrel.2005.04.003","journal-title":"J Control Release"},{"issue":"3","key":"1502_CR93","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2006.08.001","volume":"115","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ichihara M, Wang X, Kiwada H (2006) Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 115(3):243\u2013250. doi: 10.1016\/j.jconrel.2006.08.001","journal-title":"J Control Release"},{"issue":"1","key":"1502_CR94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","volume":"112","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H (2006) Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 112(1):15\u201325. doi: 10.1016\/j.jconrel.2006.01.005","journal-title":"J Control Release"},{"issue":"1\u20132","key":"1502_CR95","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijpharm.2010.03.022","volume":"392","author":"H Koide","year":"2010","unstructured":"Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N (2010) T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm 392(1\u20132):218\u2013223. doi: 10.1016\/j.ijpharm.2010.03.022","journal-title":"Int J Pharm"},{"issue":"2","key":"1502_CR96","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2005.09.014","volume":"13","author":"A Judge","year":"2006","unstructured":"Judge A, McClintock K, Phelps JR, Maclachlan I (2006) Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 13(2):328\u2013337. doi: 10.1016\/j.ymthe.2005.09.014","journal-title":"Mol Ther"},{"issue":"3","key":"1502_CR97","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.104.078113","volume":"312","author":"SC Semple","year":"2005","unstructured":"Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther 312(3):1020\u20131026. doi: 10.1124\/jpet.104.078113","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1502_CR98","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jconrel.2009.04.006","volume":"137","author":"T Tagami","year":"2009","unstructured":"Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H (2009) Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release 137(3):234\u2013240. doi: 10.1016\/j.jconrel.2009.04.006","journal-title":"J Control Release"},{"issue":"2","key":"1502_CR99","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2010.12.013","volume":"151","author":"T Tagami","year":"2011","unstructured":"Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H (2011) Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release 151(2):149\u2013154. doi: 10.1016\/j.jconrel.2010.12.013","journal-title":"J Control Release"},{"issue":"15","key":"1502_CR100","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.addr.2012.06.007","volume":"64","author":"SA Barros","year":"2012","unstructured":"Barros SA, Gollob JA (2012) Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 64(15):1730\u20131737. doi: 10.1016\/j.addr.2012.06.007","journal-title":"Adv Drug Deliv Rev"},{"issue":"19","key":"1502_CR101","doi-asserted-by":"crossref","first-page":"8984","DOI":"10.1158\/0008-5472.CAN-05-0565","volume":"65","author":"S Hu-Lieskovan","year":"2005","unstructured":"Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing\u2019s sarcoma. Cancer Res 65(19):8984\u20138992. doi: 10.1158\/0008-5472.CAN-05-0565","journal-title":"Cancer Res"},{"issue":"10","key":"1502_CR102","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","volume":"2","author":"TM Allen","year":"2002","unstructured":"Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750\u2013763. doi: 10.1038\/nrc903","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1502_CR103","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbamem.2009.12.001","volume":"1798","author":"AO Santos","year":"2010","unstructured":"Santos AO, da Silva LC, Bimbo LM, de Lima MC, Simoes S, Moreira JN (2010) Design of peptide-targeted liposomes containing nucleic acids. Biochim Biophys Acta 1798(3):433\u2013441. doi: 10.1016\/j.bbamem.2009.12.001","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"1502_CR104","first-page":"3968","volume":"50","author":"PJ Woll","year":"1990","unstructured":"Woll PJ, Rozengurt E (1990) A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res 50(13):3968\u20133973","journal-title":"Cancer Res"},{"issue":"3","key":"1502_CR105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1078\/0171-9335-00363","volume":"83","author":"S Mishra","year":"2004","unstructured":"Mishra S, Webster P, Davis ME (2004) PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 83(3):97\u2013111","journal-title":"Eur J Cell Biol"},{"issue":"1","key":"1502_CR106","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.mt.6300323","volume":"16","author":"SD Li","year":"2008","unstructured":"Li SD, Chen YC, Hackett MJ, Huang L (2008) Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16(1):163\u2013169. doi: 10.1038\/sj.mt.6300323","journal-title":"Mol Ther"},{"issue":"5","key":"1502_CR107","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/mt.2008.51","volume":"16","author":"SD Li","year":"2008","unstructured":"Li SD, Chono S, Huang L (2008) Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 16(5):942\u2013946. doi: 10.1038\/mt.2008.51","journal-title":"Mol Ther"},{"issue":"13","key":"1502_CR108","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1016\/j.biomaterials.2011.01.034","volume":"32","author":"J Gao","year":"2011","unstructured":"Gao J, Liu W, Xia Y, Li W, Sun J, Chen H, Li B, Zhang D, Qian W, Meng Y, Deng L, Wang H, Chen J, Guo Y (2011) The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32(13):3459\u20133470. doi: 10.1016\/j.biomaterials.2011.01.034","journal-title":"Biomaterials"},{"issue":"1","key":"1502_CR109","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.biomaterials.2011.09.035","volume":"33","author":"J Gao","year":"2012","unstructured":"Gao J, Yu Y, Zhang Y, Song J, Chen H, Li W, Qian W, Deng L, Kou G, Chen J, Guo Y (2012) EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials 33(1):270\u2013282. doi: 10.1016\/j.biomaterials.2011.09.035","journal-title":"Biomaterials"},{"issue":"5","key":"1502_CR110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/bit.22858","volume":"107","author":"LS Mendonca","year":"2010","unstructured":"Mendonca LS, Moreira JN, de Lima MC, Simoes S (2010) Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng 107(5):884\u2013893. doi: 10.1002\/bit.22858","journal-title":"Biotechnol Bioeng"},{"issue":"2","key":"1502_CR111","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2006.02.011","volume":"112","author":"SJ Chiu","year":"2006","unstructured":"Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ (2006) Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 112(2):199\u2013207. doi: 10.1016\/j.jconrel.2006.02.011","journal-title":"J Control Release"},{"issue":"2A","key":"1502_CR112","first-page":"1049","volume":"26","author":"SJ Chiu","year":"2006","unstructured":"Chiu SJ, Marcucci G, Lee RJ (2006) Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes. Anticancer Res 26(2A):1049\u20131056","journal-title":"Anticancer Res"},{"issue":"2","key":"1502_CR113","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jconrel.2003.11.021","volume":"95","author":"L Yang","year":"2004","unstructured":"Yang L, Li J, Zhou W, Yuan X, Li S (2004) Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells. J Control Release 95(2):321\u2013331. doi: 10.1016\/j.jconrel.2003.11.021","journal-title":"J Control Release"},{"issue":"12","key":"1502_CR114","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00383-010-2703-5","volume":"26","author":"C Feng","year":"2010","unstructured":"Feng C, Wang T, Tang R, Wang J, Long H, Gao X, Tang S (2010) Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int 26(12):1185\u20131191. doi: 10.1007\/s00383-010-2703-5","journal-title":"Pediatr Surg Int"},{"issue":"3","key":"1502_CR115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jgm.1006","volume":"9","author":"AL Cardoso","year":"2007","unstructured":"Cardoso AL, Simoes S, de Almeida LP, Pelisek J, Culmsee C, Wagner E, Pedroso de Lima MC (2007) siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med 9(3):170\u2013183. doi: 10.1002\/jgm.1006","journal-title":"J Gene Med"},{"issue":"7291","key":"1502_CR116","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067\u20131070. doi: 10.1038\/nature08956","journal-title":"Nature"},{"issue":"8","key":"1502_CR117","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1158\/0008-5472.CAN-09-3379","volume":"70","author":"W Lu","year":"2010","unstructured":"Lu W, Zhang G, Zhang R, Flores LG 2nd, Huang Q, Gelovani JG, Li C (2010) Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res 70(8):3177\u20133188. doi: 10.1158\/0008-5472.CAN-09-3379","journal-title":"Cancer Res"},{"issue":"5","key":"1502_CR118","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0163-7827(03)00032-8","volume":"42","author":"P Sapra","year":"2003","unstructured":"Sapra P, Allen TM (2003) Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42(5):439\u2013462 (pii:S0163782703000328)","journal-title":"Prog Lipid Res"},{"issue":"4","key":"1502_CR119","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/156720105774370159","volume":"2","author":"P Sapra","year":"2005","unstructured":"Sapra P, Tyagi P, Allen TM (2005) Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2(4):369\u2013381","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"1502_CR120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2867-13-65","volume":"13","author":"Q Zhu","year":"2013","unstructured":"Zhu Q, Feng C, Liao W, Zhang Y, Tang S (2013) Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer Cell Int 13(1):65. doi: 10.1186\/1475-2867-13-65","journal-title":"Cancer Cell Int"},{"issue":"1\u20132","key":"1502_CR121","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0005-2736(00)00342-4","volume":"1510","author":"MT Cruz da","year":"2001","unstructured":"da Cruz MT, Simoes S, Pires PP, Nir S, de Lima MC (2001) Kinetic analysis of the initial steps involved in lipoplex\u2013cell interactions: effect of various factors that influence transfection activity. Biochim Biophys Acta 1510(1\u20132):136\u2013151 (pii:S0005273600003424)","journal-title":"Biochim Biophys Acta"},{"issue":"39","key":"1502_CR122","doi-asserted-by":"crossref","first-page":"15549","DOI":"10.1073\/pnas.0707461104","volume":"104","author":"DW Bartlett","year":"2007","unstructured":"Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104(39):15549\u201315554. doi: 10.1073\/pnas.0707461104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17\u201318","key":"1502_CR123","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.drudis.2006.07.005","volume":"11","author":"AK Iyer","year":"2006","unstructured":"Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11(17\u201318):812\u2013818. doi: 10.1016\/j.drudis.2006.07.005","journal-title":"Drug Discov Today"},{"issue":"4","key":"1502_CR124","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","volume":"5","author":"SD Li","year":"2008","unstructured":"Li SD, Huang L (2008) Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5(4):496\u2013504. doi: 10.1021\/mp800049w","journal-title":"Mol Pharm"},{"issue":"6 Suppl 16","key":"1502_CR125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","volume":"29","author":"J Folkman","year":"2002","unstructured":"Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15\u201318. doi: 10.1053\/sonc.2002.37263","journal-title":"Semin Oncol"},{"issue":"1\u20132","key":"1502_CR126","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drup.2009.12.001","volume":"13","author":"A Abdollahi","year":"2010","unstructured":"Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 13(1\u20132):16\u201328. doi: 10.1016\/j.drup.2009.12.001","journal-title":"Drug Resist Updat"},{"issue":"1","key":"1502_CR127","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00441-008-0676-7","volume":"335","author":"E Simone","year":"2009","unstructured":"Simone E, Ding BS, Muzykantov V (2009) Targeted delivery of therapeutics to endothelium. Cell Tissue Res 335(1):283\u2013300. doi: 10.1007\/s00441-008-0676-7","journal-title":"Cell Tissue Res"},{"issue":"2","key":"1502_CR128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/mi.6.2.7","volume":"6","author":"BS Ding","year":"2006","unstructured":"Ding BS, Dziubla T, Shuvaev VV, Muro S, Muzykantov VR (2006) Advanced drug delivery systems that target the vascular endothelium. Mol Interv 6(2):98\u2013112. doi: 10.1124\/mi.6.2.7","journal-title":"Mol Interv"},{"issue":"3","key":"1502_CR129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tcm.2006.01.003","volume":"16","author":"A Hajitou","year":"2006","unstructured":"Hajitou A, Pasqualini R, Arap W (2006) Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16(3):80\u201388. doi: 10.1016\/j.tcm.2006.01.003","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"1502_CR130","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/mt.2009.291","volume":"18","author":"Y Chen","year":"2010","unstructured":"Chen Y, Wu JJ, Huang L (2010) Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 18(4):828\u2013834. doi: 10.1038\/mt.2009.291","journal-title":"Mol Ther"},{"issue":"11","key":"1502_CR131","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.062189599","volume":"99","author":"K Porkka","year":"2002","unstructured":"Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E (2002) A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 99(11):7444\u20137449. doi: 10.1073\/pnas.062189599","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1502_CR132","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200304132","volume":"163","author":"S Christian","year":"2003","unstructured":"Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163(4):871\u2013878. doi: 10.1083\/jcb.200304132","journal-title":"J Cell Biol"},{"issue":"1\u20132","key":"1502_CR133","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2012.05.018","volume":"434","author":"LC Gomes-da-Silva","year":"2012","unstructured":"Gomes-da-Silva LC, Santos AO, Bimbo LM, Moura V, Ramalho JS, Pedroso de Lima MC, Simoes S, Moreira JN (2012) Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int J Pharm 434(1\u20132):9\u201319. doi: 10.1016\/j.ijpharm.2012.05.018","journal-title":"Int J Pharm"},{"key":"1502_CR134","author":"LC Gomes-da-Silva","year":"2013","unstructured":"Gomes-da-Silva LC, Fernandez Y, Abasolo I, Schwartz S, Ramalho JS, Pedroso de Lima MC, Simoes S, Moreira JN (2013) Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform. Nanomedicine (Lond). doi: 10.2217\/nnm.12.174","journal-title":"Nanomedicine (Lond)"},{"key":"1502_CR135","author":"LC Gomes-da-Silva","year":"2013","unstructured":"Gomes-da-Silva LC, Ramalho JS, Pedroso de Lima MC, Simoes S, Moreira JN (2013) Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells. Eur J Pharm Biopharm. doi: 10.1016\/j.ejpb.2013.04.007","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"1502_CR136","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-011-1688-7","volume":"133","author":"V Moura","year":"2012","unstructured":"Moura V, Lacerda M, Figueiredo P, Corvo ML, Cruz ME, Soares R, de Lima MC, Simoes S, Moreira JN (2012) Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer. Breast Cancer Res Treat 133(1):61\u201373. doi: 10.1007\/s10549-011-1688-7","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1502_CR137","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5414\/CPP50076","volume":"50","author":"D Strumberg","year":"2012","unstructured":"Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, Giese K, Kaufmann J, Drevs J (2012) Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 50(1):76\u201378 (pii:9341)","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-013-1502-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-013-1502-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-013-1502-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T20:18:33Z","timestamp":1746044313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-013-1502-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":137,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1007\/s00018-013-1502-2","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]}}}